Poster: A Novel LC-MS/MS Assay for Quantifying Dermatan Sulfate as a…
Accumulation of dermatan sulfate (DS) in tissue and body fluid leads to mucopolysaccharidosis II (MPS II) disorder. The study aims to develop an LC-MS/MS assay to measure DS in human cerebrospinal fluid (CSF) as a biomarker.
Fact Sheet: Bioanalytical Overview
Frontage Laboratories provides bioanalytical services to help support your full drug development. Our state-of-the-art equipment and experienced personnel will quickly and efficiently provide you with the data to support your programs. We provide the resources of a highly skilled, client- focused staff with extensive academic, scientific and pharmaceutical industry experience.
Expert Interview: Gene Therapy
Overcoming the Challenges in Bioanalysis of Oligonucleotide-based Therapies and Relevance to the Clinical Development Plan
“Gene therapy provides the hope of actual cures. These therapies still have many challenges to overcome before they will become widely developed therapeutic options.” Featuring Frontage's Chief Business Officer, Hugh Davis, and Vice President of Biologics Services, Weiping Shao
Poster: Development and Validation of an Ultra Sensitive LC-MS/MS Method for…
Midazolam is a widely used central nervous system depressant. It is used for the treatment of insomnia, seizure, and induction of sedation or amnesia for operations. Midazolam is metabolized by cytochrome CYP3A. It is a widely used probing drug for evaluation of CYP3A activity in drug-to-drug interaction (DDI) studies.
Consistent with our company’s vision, mission and values, we are committed to pursuing the sustainability initiatives which is an integral part of our business and goes beyond economic, legal or regulatory motives. At Frontage, we have implemented sustainability frame work that promotes long lasting values for our people, customers and all stakeholders.